NICE technology appraisal guidance
Issued: February 2010
TA186
Certolizumab pegol for the treatment of rheumatoid arthritis
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta186
Important information about this guidance
This guidance was developed using the NICE single technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp